Expanding the clingen lysosomal storage disorder curation effort: vceps for mucopolysaccharidosis type II and iiia

Active Cooperative Agreement Awarded

Award ID
U24HD121485
Recipient
Awarding agency
Obligated
$352,880

Award facts

Completion date 6% complete
Place of performance
Rochester, MN 55905, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Child Health and Human Development awarded Mayo Clinic $352,880 under Cooperative Agreement U24HD121485, "Expanding the ClinGen Lysosomal Storage Disorder Curation Effort: VCEPs for Mucopolysaccharidosis Type II and IIIA," on September 23, 2026. The award is funded through Child Health and Human Development Extramural Research (CFDA 93.865).

The award expands the ClinGen Lysosomal Diseases Variant Curation Expert Panel (LD VCEP), co-led by Drs. Filippo Pinto E Vairo, Lorne Clarke, Catherine Rehder, and Jennifer Goldstein, to include expert curation of IDS and SGSH variants associated with mucopolysaccharidosis type II (MPS II) and type IIIA (MPS IIIA). The recipient will establish gene-specific criteria for IDS and SGSH, curate and classify high-priority variants, and disseminate results through ClinVar and the ClinGen Evidence Repository. The work builds on the panel's prior implementation of ACMG/AMP-based variant interpretation guidelines for IDUA and GAA. The source states that MPS II was recently added to the U.S. Recommended Uniform Screening Panel for newborn screening.

Place of performance is Rochester, MN 55905, USA, with an ultimate completion date of August 31, 2029.

Description

Abstract
Lysosomal diseases (LDS) are a group of over 70 rare, inherited monogenic disorders caused by deficiencies in lysosomal enzymes, transporters, or related proteins, resulting in progressive accumulation of toxic substrates and multisystem disease. Among LDS, mucopolysaccharidosis type II (MPS II) and type iiia (MPS iiia) are particularly severe, characterized by early-onset neurocognitive decline, somatic complications, and premature death. These disorders exemplify the diagnostic and clinical management challenges in LDS: broad phenotypic variability, frequent identification of novel or rare variants, and a high proportion of variants of uncertain significance (VUS) in the associated genes IDS and sgsh. The lack of standardized, expert-reviewed variant classification frameworks delays access to care, and complicates eligibility for emerging therapies and clinical trials. This proposal aims to address these gaps by expanding the scope of the clingen lysosomal diseases variant curation expert panel (LD vcep), CO-led by DRS. Filippo pinto E vairo, lorne clarke, catherine rehder, and jennifer goldstein to include expert curation of IDS and sgsh. The panel has already demonstrated success by implementing acmg/AMP-based variant interpretation guidelines for idua and GAA, the genes implicated in MPS I and pompe disease. Building on this foundation, our project will establish gene-specific criteria for IDS and sgsh, curate and classify high-priority variants, and disseminate results through clinvar and the clingen evidence repository. Our rationale for prioritizing MPS II and iiia is threefold: (1) both conditions are clinically devastating and lack curated, standardized variant interpretation resources; (2) MPS II has recently been added to the U.S. Recommended uniform screening panel (RUSP) for newborn screening, and MPS iiia is being piloted in screening programs; and (3) both disorders are targets for emerging gene and enzyme replacement therapies, making accurate molecular diagnosis critical. These factors create a time-sensitive need for expert variant interpretation to support newborn screening follow-up, clinical decision-making, and therapeutic access. The proposed work will be carried out through three specific aims: (1) expert curation and classification of IDS variants using customized acmg/AMP criteria; (2) expert curation and classification of sgsh variants, addressing both classical and atypical phenotypes; and (3) establishment of a sustainable model for annual variant reclassification, stakeholder engagement, and dissemination. The project will be led by a multidisciplinary consortium of clinical and molecular geneticists, biochemical geneticists, bioinformaticians, genetic counselors, and patient advocacy partners, supported by strong institutional infrastructure and national and international collaborations. This initiative aligns directly with the goals of PAR-23-199 by advancing expert-driven, transparent, and publicly accessible variant interpretation in clinically actionable genes. In addition to reducing VUS burden and improving diagnostic clarity for MPS II and iiia, this project will create a scalable framework to support future expansion of the LD vcep to additional lysosomal disease genes.

Quick answers

Who received award U24HD121485?

U24HD121485 was awarded to Mayo Clinic by National Institute of Child Health and Human Development (National Institutes of Health) on September 23, 2026.

How much is award U24HD121485 worth?

$352,880 has been obligated on U24HD121485.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award